The data published from the prospective Diabetes Prevention with Active Vitamin D (DPVD) trial online in the British Medical Journal disclosed that vitamin D supplementation doesnt reduce the risk of developing type 2 diabetes among the prediabetics, but benefits those with low insulin secretion.

The study had a total of 1256 participants. At baseline, the average blood 25-hydroxyvitamin D concentration was 20.9 ng/mL (52.2 nmol/L); 43.6% of the people had values much less than 20 ng/mL. Over three years, 12.5% of the 630 eldecalcitol patients and 14.2% of the 626 placebo patients developed diabetes (hazard ratio 0.87, 95% confidence interval 0.67 to 1.17; P=0.39). There was also no difference in normoglycemia regression, which occurred in 23.0 % of eldecalcitol patients versus 20.1 % of placebo patients by the end of the research (P =.21).

After adjusting for predetermined covariates, eldecalcitol was found to be efficacious in avoiding the development of type 2 diabetes (hazard ratio [HR], 0.69; P =.02). According to findings from the type 2 diabetes study, maximum benefited groups included prediabetics having low vitamin d levels and non-obese benefited the most and those with higher vitamin D blood levels, but that large supplemented dosages may have impaired musculoskeletal effects in the elderly.

Although eldecalcitol medication did not significantly lower the incidence of diabetes in patients with pre-diabetes, the findings revealed that eldecalcitol could have a favourable effect on people who had insufficient insulin secretion. (Medscape Medical News, May 26, 2022)